Supernus Pharmaceuticals, Inc.
SUPN
$32.22
$0.872.78%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -0.87% | 4.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -0.87% | 4.37% | |||
| Cost of Revenue | 48.43% | -1.86% | |||
| Gross Profit | -6.35% | 5.12% | |||
| SG&A Expenses | 0.44% | -5.41% | |||
| Depreciation & Amortization | -6.38% | -3.08% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.91% | -1.83% | |||
| Operating Income | -30.95% | 55.53% | |||
| Income Before Tax | -41.30% | 70.87% | |||
| Income Tax Expenses | 71.49% | 0.94% | |||
| Earnings from Continuing Operations | -60.18% | 93.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -60.18% | 93.30% | |||
| EBIT | -30.95% | 55.53% | |||
| EBITDA | -20.70% | 24.40% | |||
| EPS Basic | -60.40% | 92.71% | |||
| Normalized Basic EPS | -24.79% | 47.29% | |||
| EPS Diluted | -60.77% | 91.67% | |||
| Normalized Diluted EPS | -24.96% | 46.95% | |||
| Average Basic Shares Outstanding | 0.57% | 0.31% | |||
| Average Diluted Shares Outstanding | 0.80% | 0.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||